• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes.

作者信息

Lawler Patrick R, Liu Hongyan, Frankfurter Claudia, Lovblom Leif Erik, Lytvyn Yuliya, Burger Dylan, Burns Kevin D, Brinc Davor, Cherney David Z I

机构信息

Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.

Ted Rogers Centre for Heart Research, University of Toronto, Toronto, Ontario, Canada.

出版信息

Diabetes Care. 2021 Mar;44(3):e45-e47. doi: 10.2337/dc20-2265. Epub 2021 Jan 12.

DOI:10.2337/dc20-2265
PMID:33436398
Abstract
摘要

相似文献

1
Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes.慢性肾脏病合并2型糖尿病患者中与钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂依鲁格列净相关的心血管生物标志物变化
Diabetes Care. 2021 Mar;44(3):e45-e47. doi: 10.2337/dc20-2265. Epub 2021 Jan 12.
2
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.依格列净对糖尿和利钠生物标志物的差异影响：VERTIS CV 的预设分析。
Diabetes Obes Metab. 2022 Jun;24(6):1114-1122. doi: 10.1111/dom.14677. Epub 2022 Mar 28.
3
The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.肾功能损害对2型糖尿病患者中恩格列净药代动力学和药效学的影响。
J Clin Pharmacol. 2017 Nov;57(11):1432-1443. doi: 10.1002/jcph.955. Epub 2017 Jul 13.
4
Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.厄格列净的临床药理学概述：一种新型的钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂。
Clin Pharmacokinet. 2020 Aug;59(8):949-965. doi: 10.1007/s40262-020-00875-1.
5
Ertugliflozin for the treatment of type 2 diabetes.恩格列净用于治疗2型糖尿病。
Drugs Today (Barc). 2019 Mar;55(3):167-175. doi: 10.1358/dot.2019.55.3.2904972.
6
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾脏和心脏影响：科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
7
Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.依帕列净单药治疗 2 型糖尿病。
Expert Opin Pharmacother. 2018 Nov;19(16):1841-1847. doi: 10.1080/14656566.2018.1525360. Epub 2018 Sep 24.
8
Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.重点更新：心力衰竭和/或慢性肾脏病患者的 SGLT2 抑制剂。
Ann Pharmacother. 2021 Feb;55(2):252-260. doi: 10.1177/1060028020934001. Epub 2020 Jun 13.
9
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.厄格列净对 2 型糖尿病患者心力衰竭和肾脏结局影响的介导因素。
Diabetes Obes Metab. 2022 Sep;24(9):1829-1839. doi: 10.1111/dom.14769. Epub 2022 Jun 15.
10
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.SGLT2 抑制剂的肾脏和心血管保护机制评估：基于模型的临床数据分析。
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.

引用本文的文献

1
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure.恩格列净在2型糖尿病合并心力衰竭患者中的机制评估
Physiol Rep. 2025 Apr;13(7):e70275. doi: 10.14814/phy2.70275.
2
Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors.启动SGLT-2或DPP-4抑制剂后高钾血症与肾素-血管紧张素系统抑制剂治疗的维持
Nephrol Dial Transplant. 2025 Apr 28;40(5):956-966. doi: 10.1093/ndt/gfae227.
3
Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin-a post-hoc analysis of the UTOPIA study.
使用托格列净治疗的2型糖尿病患者血清肝脏相关参数、尿酸和血红蛋白水平的变化——UTOPIA研究的事后分析
Diabetol Int. 2024 Feb 10;15(3):379-388. doi: 10.1007/s13340-024-00693-x. eCollection 2024 Jul.
4
Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.联合药物治疗在 2 型糖尿病相关慢性肾脏病中的肾脏和心血管保护作用。
BMC Nephrol. 2024 Aug 1;25(1):248. doi: 10.1186/s12882-024-03652-5.
5
Sodium glucose transporter 2 inhibitors: Will these drugs benefit non-diabetic veterinary patients with cardiac and kidney diseases?钠葡萄糖协同转运蛋白2抑制剂：这些药物会使患有心脏和肾脏疾病的非糖尿病兽医患者受益吗？
J Vet Pharmacol Ther. 2025 Jan;48 Suppl 1(Suppl 1):1-18. doi: 10.1111/jvp.13472. Epub 2024 Jul 13.
6
SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：肾脏病学家的一种具有广泛影响的治疗选择。
Front Nephrol. 2022 Apr 29;2:867075. doi: 10.3389/fneph.2022.867075. eCollection 2022.
7
Managing Hyperkalemia in the Modern Era: A Case-Based Approach.现代高钾血症的管理：基于病例的方法。
Kidney Int Rep. 2023 Apr 24;8(7):1290-1300. doi: 10.1016/j.ekir.2023.04.016. eCollection 2023 Jul.
8
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.SGLT2 抑制剂在伴有糖尿病肾病的 1 型糖尿病中的应用：潜在的心肾获益可能超过可预防的糖尿病酮症酸中毒风险。
Curr Diab Rep. 2022 Jul;22(7):317-332. doi: 10.1007/s11892-022-01471-2. Epub 2022 May 28.
9
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.厄格列净对 2 型糖尿病患者心力衰竭和肾脏结局影响的介导因素。
Diabetes Obes Metab. 2022 Sep;24(9):1829-1839. doi: 10.1111/dom.14769. Epub 2022 Jun 15.
10
Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys.心肾综合征：心脏与肾脏之间神经联系的作用。
Circ Res. 2022 May 13;130(10):1601-1617. doi: 10.1161/CIRCRESAHA.122.319989. Epub 2022 May 12.